Probable Interaction Between Warfarin and Torsemide

Objective: To report a case in which the anticoagulation effect of warfarin appeared to be potentiated by torsemide, possibly due to an interference of metabolism through competition for the CYP2C9 isoenzyme and protein-binding displacement of warfarin. Case Summary: A 43-year-old Hispanic female with congestive heart failure, hypothyroidism, anemia, atrial fibrillation, and a mitral mechanical valve replacement was effectively anticoagulated with a target international normalized ratio (INR) of 2.5–3.5 on a warfarin regimen of 50–52.5 mg/wk. One week following the initiation of torsemide 40 mg in the morning and 20 mg in the afternoon, a marked increase in the INR occurred (6.2), requiring a warfarin dosage reduction. Subsequent titrations over a 3-week period eventually resulted in the achievement of a therapeutic INR (from 3.3 to 2.9) with a new warfarin regimen of 47.5 mg/wk. Discussion: Both torsemide and warfarin are highly protein-bound to albumin and are major substrates for the CYP2C9 isoenzyme. Competition by multiple drugs for metabolism via CYP2C9 may decrease the clearance of the drugs from systemic circulation. Addition of a drug with high protein binding may result in the displacement of other drugs that circulate highly protein-bound. Therefore, it is possible that the addition of torsemide may potentiate the anticoagulant effect of warfarin by (1) competition for metabolism through CYP2C9, with a decrease in the clearance of warfarin, and (2) protein-binding displacement of warfarin from albumin, transiently potentiating anticoagulant activity. An objective causality assessment revealed that the interaction was probable. Cardiology records confirmed the absence of fluid and heart failure status changes; therefore, these were ruled out as potential etiologies. No levothyroxine dosage changes occurred over the previous 14 months; thus, this also was ruled out as a possible etiology. Conclusions: To our knowledge, an interaction between warfarin and torsemide has not been previously reported. While further research should be done to confirm this interaction, practitioners should be made aware of its possibility.

[1]  F. Deckert Ascorbic acid and warfarin. , 1973, JAMA.

[2]  Mark Crowther,et al.  Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[3]  P. Griner,et al.  Warfarin and ascorbic acid: lack of evidence for a drug interaction. , 1974, Toxicology and Applied Pharmacology.

[4]  L. Sansom,et al.  What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions? , 1995, Drug safety.

[5]  T. Self,et al.  Does heart failure exacerbation increase response to warfarin?A critical review of the literature , 2006, Current medical research and opinion.

[6]  F. Kamali,et al.  Dietary related plasma vitamin C concentration has no effect on anticoagulation response to warfarin. , 2006, Thrombosis research.

[7]  J. Miners,et al.  Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. , 2000, Pharmacogenetics.

[8]  R. Hume,et al.  Interaction of ascorbic acid and warfarin. , 1972, JAMA.

[9]  G. C. Johnson,et al.  Interaction of ascorbic acid and warfarin. , 1972, JAMA.

[10]  C. Feetam,et al.  Lack of a clinically important interaction between warfarin and ascorbic acid. , 1975, Toxicology and applied pharmacology.

[11]  M. Sahud,et al.  IMPACT OF ASPIRIN AND CHLORTHALIDONE ON THE PHARMACODYNAMICS OF ORAL ANTICOAGULANT DRUGS IN MAN * , 1971, Annals of the New York Academy of Sciences.

[12]  D. Robinson,et al.  The Effect of Furosemide and Bumetanide on Warfarin Metabolism and Anticoagulant Response , 1978, Journal of clinical pharmacology.

[13]  Daniel Kurnik,et al.  Complex Drug-Drug-Disease Interactions Between Amiodarone, Warfarin, and the Thyroid Gland , 2004, Medicine.

[14]  D. Greenblatt,et al.  Interaction of Warfarin With Drugs, Natural Substances, and Foods , 2005, Journal of clinical pharmacology.

[15]  D. Juurlink Drug interactions with warfarin: what clinicians need to know , 2007, Canadian Medical Association Journal.

[16]  John R Horn,et al.  Proposal for a New Tool to Evaluate Drug Interaction Cases , 2007, The Annals of pharmacotherapy.

[17]  T. Self,et al.  Decreased hypoprothrombinemic effect of warfarin associated with furosemide. , 1997, Therapeutic drug monitoring.

[18]  J. Miners,et al.  Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[19]  F. Iber,et al.  The Effect of Bumetanide on the Serum Disappearance of Warfarin Sodium , 1981, Journal of clinical pharmacology.

[20]  M A Stephens,et al.  Response to Warfarin and Other Oral Anticoagulants: Effects of Disease States , 2000, Southern medical journal.